Abstract
Delayed hematopoietic engraftment, particularly of platelets, is seen in 5–35% of patients undergoing high-dose chemotherapy with autologous stem cell transplantation. Studies indicate that delayed engraftment is related to low CD34+ cell dose, and that risk factors for poor mobilization of CD34+ cells relate primarily to the type and extent of prior therapy. Data indicating an appropriate strategy to ensure that ‘hard-to-mobilize’ patients will achieve adequate CD34+ cell numbers are limited. It is clear, however, that marrow harvesting (performed frequently by a number of centers), is of limited value. Remobilization, best accomplished with a regimen of high-dose chemotherapy and cytokines, is of benefit in selected patients, but has substantial costs and morbidity. Instead of ad hoc treatment of patients who have a poor first mobilization, high-risk groups should be identified prospectively, and strategies should be developed to ensure adequate mobilization in all high-risk patients. The first randomized trial utilizing this approach has recently been reported. In this trial, stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) alone was compared to mobilization with G-CSF combined with stem cell factor (SCF) in heavily pretreated patients with Hodgkin’s and non-Hodgkin’s lymphoma. The combination of G-CSF and SCF led to collection of a higher total CD34+ cell dose compared to G-CSF alone. Further, more patients in the combination group were able to mobilize an optimal CD34+ cell dose (ie 5 × 106/kg). Additional trials are needed to determine long-term outcomes and the economic impact of achieving optimal stem cell mobilization in these patients, who would otherwise not be candidates for high-dose chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stiff, P. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 23 (Suppl 2), S29–S33 (1999). https://doi.org/10.1038/sj.bmt.1701671
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701671
Keywords
This article is cited by
-
Development and validation of a predictive model to guide the use of plerixafor in pediatric population
Bone Marrow Transplantation (2022)
-
Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
BMC Cancer (2019)
-
A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation
Bone Marrow Transplantation (2017)
-
Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting
Indian Journal of Hematology and Blood Transfusion (2017)
-
Prediction model for CD34 positive cell yield in peripheral blood stem cell collection on the fourth day after G-CSF administration in healthy donors
International Journal of Hematology (2013)